Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 1, 2013
Every year, Frost & Sullivan recognizes companies in a variety of markets for demonstrating outstanding performance in areas including business growth, technical innovation, customer service and product development.
A number of unique measurement indicators were taken into account for the Product Line Strategy Award. The criteria for the award included breadth of product line, size of addressable customer base, impact on customer value, market share and extent of applications and markets served.
"It is with great pleasure that we accept this prestigious accolade from Frost & Sullivan, not only does the award recognize the ongoing investments we make in our ingredients portfolio and technical capabilities, it is also an invaluable endorsement of our customer-centric, science-led approach to product development," said Hans Langereis, vice president global sales and marketing, Rousselot.
The competitive analysis revealed that the flexibility of services Rousselot offers its customers is unmatched by its competitors within the collagen peptide industry. Frost & Sullivan awarded the Global Product Line Strategy Award to Rousselot due to the unrivaled product offering, extensive customer support and proven efficacy of its Peptan range.
"Under the flagship Peptan brand, Rousselot has been very proactive in launching highly-targeted and scientifically-proven products in multiple formats, which cut across applications and meet specific consumer requirements," said Christopher J. Shananhan, global program manager for Food and Agriculture, Frost & Sullivan. "Combined with its unmatched customer support and unique production capabilities, Rousselot is a standout company among its peers and we are proud to present them with the 2013 Product Line Strategy Award."
You May Also Like
Here's why creatine sales are surging this past yearFeb 21, 2024
DSHEA's 25th anniversary: Industry vets, critics respondFeb 21, 2024
The Month in 2: Sports – videoFeb 21, 2024
Tianeptine sales spur another FDA warning, action by state lawmakersFeb 20, 2024